Biotech firms should review co-development agreements to ensure clear alignment on drug trial timelines.
Live Poll
Should large pharmaceutical companies be held liable for damages in broken development partnerships?
September 24, 2026
Trilliant Health Launched AI Platform for Hospital StrategyThe enterprise software aims to replace manual consulting services for hospital systems.
September 24, 2026
Basalt Health Secured $20 Million Series A FundingThe startup will scale its post-acute care automation platform to 111 enterprise markets by late 2026.
September 24, 2026
AI-Driven Billing Added $1 Billion to Healthcare CostsHealthcare providers using automated coding tools have increased claims volume, creating new cost pressures for insurers.
September 24, 2026
Oracle Targeted Clinical Quality to Lower Health CostsHealthcare operators are using automated AI tools to streamline prior authorization and monitor patient health.
September 24, 2026
PhRMA Urged Congress to Reauthorize Biosimilar Fee ProgramHealthcare operators and manufacturers face potential shifts in regulatory review timelines for biosimilar drugs.
September 24, 2026
Healthcare Protests Followed Medicaid Funding CutsOperators of medical facilities face shifting patient coverage and revenue models as federal policy changes tighten eligibility.
September 24, 2026
Senator Questioned FDA Nominee on Agency IndependenceThe hearing focused on whether future FDA commissioners will prioritize regulatory integrity over external donor influence.
September 24, 2026
Senator Demanded Disclosure of Drug Pricing AgreementsSenate Finance Committee members are seeking transparency into pharmaceutical deals before confirming an HHS nominee.
September 24, 2026
Federal Court Affirmed Spinal Implant Patent RulingThe decision clarifies how patent claim language regarding device universality impacts infringement litigation for medical device manufacturers.
September 24, 2026
FDA Nominee Faced Scrutiny Over Drug Pricing ClaimsHealthcare operators should track how administration claims on drug pricing reconcile with market-level cost indicators.
